Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALKS
stocks logo

ALKS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
379.49M
-11.74%
0.426
-59.44%
388.50M
+26.75%
0.380
+30.58%
475.44M
+21.7%
0.600
-11.6%
Estimates Revision
The market is revising Upward the revenue expectations for Alkermes plc (ALKS) for FY2025, with the revenue forecasts being adjusted by 3.69% over the past three months. During the same period, the stock price has changed by -2.14%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.69%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+11.59%
In Past 3 Month
Stock Price
Go Down
down Image
-2.14%
In Past 3 Month
Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is 44.50 USD with a low forecast of 34.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is 44.50 USD with a low forecast of 34.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 29.300
sliders
Low
34.00
Averages
44.50
High
58.00
Current: 29.300
sliders
Low
34.00
Averages
44.50
High
58.00
Jefferies
Hold
downgrade
$23
2025-11-26
Reason
Jefferies
Price Target
$23
2025-11-26
downgrade
Hold
Reason
Jefferies lowered the firm's price target on Avadel Pharmaceuticals (AVDL) to $22.50 from $23 and keeps a Hold rating on the shares as the firm expects the deal to be acquired by Alkermes (ALKS) to close in Q1 of 2026 after Lundbeck decided not to raise its November 14 offer. The firm now thinks the chances of a competing bid are unlikely and lowered its target to reflect Alkermes' November 18 offer to acquire Avadel for $22.50 per share, including $21 upfront and a $1.50 per share CVR.
Guggenheim
Buy
upgrade
$28 -> $43
2025-11-18
Reason
Guggenheim
Price Target
$28 -> $43
2025-11-18
upgrade
Buy
Reason
Guggenheim raised the firm's price target on Centessa (CNTA) to $43 from $28 and keeps a Buy rating on the shares following the "promising" preliminary readout from the ORX750 CRYSTAL-1 Ph2a study as well as the "relatively underwhelming" results from alixorexton in NT2 that were reported by Alkermes (ALKS).
Truist
Buy
maintain
$50 -> $55
2025-11-17
Reason
Truist
Price Target
$50 -> $55
2025-11-17
maintain
Buy
Reason
Truist raised the firm's price target on Alkermes (ALKS) to $55 from $50 and keeps a Buy rating on the shares. Positive Vibrance-2 results materially de-risk the alixorexton program, supporting a higher probability of success and stronger estimates, the analyst tells investors in a research note. Cross-trial comparisons show alixorexton outperforming oveporexton in NT2, and the added split-dosing regimen in Phase 3 could further enhance efficacy, with Takeda (TAK) management viewing the program as credible competitive pressure.
Deutsche Bank
David Hoang
Buy
downgrade
$55 -> $45
2025-11-13
Reason
Deutsche Bank
David Hoang
Price Target
$55 -> $45
2025-11-13
downgrade
Buy
Reason
Deutsche Bank analyst David Hoang lowered the firm's price target on Alkermes to $45 from $55 and keeps a Buy rating on the shares. The company announced positive topline data from its Phase 2 VIBRANCE-2 trial of alixorexton in narcolepsy type 2, but results came in below the high expectations needed for the drug to be a "clear best-in-class therapy," the analyst tells investors in a research note. The firm believes the shares dropped yesterday on a perceived less competitive commercial profile for alixorexton versus peers.
Truist
Joon Lee
Buy
maintain
$50
2025-11-12
Reason
Truist
Joon Lee
Price Target
$50
2025-11-12
maintain
Buy
Reason
Truist analyst Joon Lee says that while Alkermes announced the dual endpoints were met in the Vibrance-2 dose-ranging Phase 2 study evaluating alixorexton in patients with narcolepsy type 2, the "details are scant." Truist is "comforted" that 95% of patients chose to enter the optional five-week open-label extension, which it believes speaks to a good benefit/risk ratio. The firm has a Buy rating on Alkermes with a $50 price target. The stock in morning trading is down 12%, or $3.94, to $29.88.
Evercore ISI
Evercore ISI
Outperform
maintain
$30.47
2025-11-12
Reason
Evercore ISI
Evercore ISI
Price Target
$30.47
2025-11-12
maintain
Outperform
Reason
Evercore ISI said the firm disagrees with the Street reaction on Alkermes (ALKS), adding that the "Street has had a confused reaction to all the new data out of Alkermes and Centessa recently." While the Street thinks the company missed the 20 minute MWT within the arm or greater than 10 minute MWT bar versus placebo, the firm contends "they didn't" and added that Alkermes avoided the "disaster scenario" of failing in narcolepsy type 2 like Takeda's (TAK) TAK-861. The firm, which thinks the Street is "grossly underestimating the clinician interest in this category for narcolepsy," has an Outperform rating on Alkermes shares, which are down $3.34, or 10% to $30.47 in morning trading.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Alkermes Plc (ALKS.O) is 14.49, compared to its 5-year average forward P/E of 95.38. For a more detailed relative valuation and DCF analysis to assess Alkermes Plc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
95.38
Current PE
14.49
Overvalued PE
245.11
Undervalued PE
-54.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
5.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
77.71
Undervalued EV/EBITDA
-67.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.60
Current PS
0.00
Overvalued PS
4.43
Undervalued PS
2.77
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ALKS News & Events

Events Timeline

(ET)
2025-12-01
08:40:00
B. Riley Raises Centessa Price Target to $42, Maintains Buy Rating
select
2025-11-19 (ET)
2025-11-19
06:11:42
Alkermes Raises Acquisition Bid for Avadel Pharmaceuticals to $22.50 per Share
select
2025-11-17 (ET)
2025-11-17
06:11:58
Avadel board determines Lundbeck's proposal is better than Alkermes' offer
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04Globenewswire
Alkermes to Acquire Avadel; Shareholder Vote Scheduled for January 2026
  • Acquisition Agreement: Alkermes has reached an agreement to acquire all issued ordinary shares of Avadel, which is expected to enhance Alkermes' market position in the biopharmaceutical sector.
  • Shareholder Voting Schedule: Avadel has begun mailing a proxy statement to shareholders, who will vote on the acquisition at a special meeting scheduled for January 12, 2026, ensuring shareholder engagement in the decision-making process.
  • Legal Compliance Procedure: The transaction will be implemented via a scheme of arrangement under Part 9 of the Irish Companies Act, ensuring adherence to relevant laws and minimizing legal risks associated with the acquisition.
  • Transparency in Information Disclosure: Avadel has filed the Definitive Proxy Statement with the SEC, ensuring shareholders receive comprehensive information prior to voting, thereby enhancing transaction transparency and shareholder trust.
[object Object]
Preview
8.5
12-04Newsfilter
Alkermes to Acquire Avadel; Shareholder Vote Scheduled for January 2026
  • Acquisition Agreement: Alkermes has reached an agreement to acquire all issued ordinary shares of Avadel, marking a strategic consolidation in the biopharmaceutical sector between the two companies.
  • Shareholder Voting Arrangement: Avadel has begun mailing a proxy statement to shareholders, who will vote on the acquisition scheme at a meeting scheduled for January 12, 2026, ensuring shareholder involvement in this critical decision.
  • Legal Compliance Process: The transaction will be implemented via a scheme of arrangement under Part 9 of the Irish Companies Act, adhering to Irish takeover rules to ensure legality and transparency in the process.
  • Market Reaction Expectations: This acquisition may impact Avadel's market performance, and investors should monitor the shareholder vote outcome and subsequent regulatory approvals to assess the transaction's final implications.
[object Object]
Preview
8.5
12-02Newsfilter
Alkermes to Acquire Avadel; Shareholder Vote Scheduled for January 12, 2026
  • Acquisition Agreement: Alkermes has reached an agreement to acquire Avadel, intending to purchase all issued ordinary shares through a scheme of arrangement under Part 9 of the Irish Companies Act, which is expected to enhance Alkermes' market position in the biopharmaceutical sector.
  • Shareholder Vote Arrangement: Avadel shareholders are scheduled to meet on January 12, 2026, to vote on the acquisition scheme, ensuring shareholder participation in decision-making that could impact the company's future ownership structure and governance.
  • Court Approval Process: The Irish High Court has directed the convening of a shareholder meeting, marking a legal compliance step in the acquisition process that ensures the transaction's legality and transparency, thereby boosting investor confidence.
  • Information Disclosure Plan: Avadel plans to mail a detailed proxy statement to shareholders around December 3, providing the full terms and conditions of the acquisition, which will help ensure shareholders are well-informed and potentially increase support for the transaction.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Alkermes Plc (ALKS) stock price today?

The current price of ALKS is 29.3 USD — it has decreased -0.78 % in the last trading day.

arrow icon

What is Alkermes Plc (ALKS)'s business?

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

arrow icon

What is the price predicton of ALKS Stock?

Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is 44.50 USD with a low forecast of 34.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Alkermes Plc (ALKS)'s revenue for the last quarter?

Alkermes Plc revenue for the last quarter amounts to 394.19M USD, increased 4.24 % YoY.

arrow icon

What is Alkermes Plc (ALKS)'s earnings per share (EPS) for the last quarter?

Alkermes Plc. EPS for the last quarter amounts to 0.49 USD, decreased -10.91 % YoY.

arrow icon

What changes have occurred in the market's expectations for Alkermes Plc (ALKS)'s fundamentals?

The market is revising Upward the revenue expectations for Alkermes plc (ALKS) for FY2025, with the revenue forecasts being adjusted by 3.69% over the past three months. During the same period, the stock price has changed by -2.14%.
arrow icon

How many employees does Alkermes Plc (ALKS). have?

Alkermes Plc (ALKS) has 1800 emplpoyees as of December 05 2025.

arrow icon

What is Alkermes Plc (ALKS) market cap?

Today ALKS has the market capitalization of 4.84B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free